{"id":"efalizumab-plus-acitretin","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Infection (upper respiratory, other)"},{"rate":null,"effect":"Cheilitis (lip inflammation)"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Efalizumab is a monoclonal antibody against CD11a that inhibits lymphocyte function-associated antigen-1 (LFA-1), preventing T-cell adhesion and migration to inflamed skin. Acitretin is a retinoid that normalizes keratinocyte differentiation and reduces inflammatory cytokine production. The combination targets both the immune activation and the abnormal skin cell proliferation characteristic of psoriasis.","oneSentence":"Efalizumab blocks T-cell activation and migration to skin while acitretin reduces keratinocyte proliferation and differentiation, together providing dual immunological and differentiation-based control of psoriasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:45:14.731Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT00707070","phase":"PHASE4","title":"Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis","status":"UNKNOWN","sponsor":"Universita di Verona","startDate":"2008-09","conditions":"Chronic Plaque Psoriasis","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"efalizumab plus acitretin","genericName":"efalizumab plus acitretin","companyName":"Universita di Verona","companyId":"universita-di-verona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Efalizumab blocks T-cell activation and migration to skin while acitretin reduces keratinocyte proliferation and differentiation, together providing dual immunological and differentiation-based control of psoriasis. Used for Moderate to severe plaque psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}